Novo Nordisk Shares Plunge on Insulin's FDA Failure

Feb. 11 (Bloomberg) -- Bloomberg's Caroline Hyde reports that Novo Nordisk shares have fallen the most in a decade as the company's new insulin drug Tresiba has failed to win FDA approval in the United States. She speaks on Bloomberg Television's "The Pulse."
Aetna to Buy Humana for $37 Billion
25:43 - Bloomberg's Francine Lacqua and Manus Cranny report on today's "Top Headlines." They speak on Bloomberg Television's "The Pulse." (Source: Bloomberg)
  • No Single Personality Can Unite Greece Now: Michaletos
  • Global Stock Market Still in Pretty Good Shape: Gilbert
  • Greek 'No' Vote Would Make Euro Exit Likely: Nakisa